[go: up one dir, main page]

CR20220457A - Formulaciones de anticuerpos anti-tslp humanos y métodos de tratamiento de una enfermedad inflamatoria - Google Patents

Formulaciones de anticuerpos anti-tslp humanos y métodos de tratamiento de una enfermedad inflamatoria

Info

Publication number
CR20220457A
CR20220457A CR20220457A CR20220457A CR20220457A CR 20220457 A CR20220457 A CR 20220457A CR 20220457 A CR20220457 A CR 20220457A CR 20220457 A CR20220457 A CR 20220457A CR 20220457 A CR20220457 A CR 20220457A
Authority
CR
Costa Rica
Prior art keywords
methods
inflammatory disease
formulations
human anti
treating inflammatory
Prior art date
Application number
CR20220457A
Other languages
English (en)
Inventor
Clea Tally
Christopher Sloey
Alexis Lueras
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of CR20220457A publication Critical patent/CR20220457A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

En la presente se proporcionan composiciones acuosas que comprenden (a) un anticuerpo anti-TSLP a una concentración mayor que aproximadamente 140 mg/ml, (b) un tensioactivo y (c) al menos un aminoácido básico o una sal del mismo. También se proporcionan composiciones acuosas que comprenden composiciones acuosas que comprenden (a) un anticuerpo anti-TSLP a una concentración mayor que aproximadamente 140 mg/ml, (b) un tensioactivo y (c) al menos una sal de calcio o sal de magnesio. También se proporcionan artículos de fabricación relacionados, jeringas precargadas y viales que comprenden las composiciones de la presente divulgación. Se proporcionan en la presente usos de las composiciones para tratar una enfermedad inflamatoria, por ejemplo, la dermatitis atópica. Además, se proporcionan en la presente métodos de preparación de un anticuerpo estable y líquido que tiene una viscosidad de menos de aproximadamente 100 cP
CR20220457A 2020-02-13 2021-02-12 Formulaciones de anticuerpos anti-tslp humanos y métodos de tratamiento de una enfermedad inflamatoria CR20220457A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062976007P 2020-02-13 2020-02-13
US202163148105P 2021-02-10 2021-02-10
PCT/US2021/017880 WO2021163504A1 (en) 2020-02-13 2021-02-12 Formulations of human anti-tslp antibodies and methods of treating inflammatory disease

Publications (1)

Publication Number Publication Date
CR20220457A true CR20220457A (es) 2023-01-09

Family

ID=74858823

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20220457A CR20220457A (es) 2020-02-13 2021-02-12 Formulaciones de anticuerpos anti-tslp humanos y métodos de tratamiento de una enfermedad inflamatoria

Country Status (18)

Country Link
US (1) US20230078678A1 (es)
EP (1) EP4103235A1 (es)
JP (1) JP2023513312A (es)
KR (1) KR20220140772A (es)
CN (1) CN115279404A (es)
AU (1) AU2021219839A1 (es)
BR (1) BR112022016010A2 (es)
CA (1) CA3166964A1 (es)
CL (1) CL2022002193A1 (es)
CO (1) CO2022012868A2 (es)
CR (1) CR20220457A (es)
IL (1) IL295042A (es)
JO (1) JOP20220183A1 (es)
MX (1) MX2022010012A (es)
PE (1) PE20230112A1 (es)
PH (1) PH12022552050A1 (es)
UY (1) UY39083A (es)
WO (1) WO2021163504A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202228776A (zh) * 2020-12-03 2022-08-01 大陸商江蘇恒瑞醫藥股份有限公司 抗tslp抗體藥物組合物及其用途
US12110324B2 (en) 2022-07-22 2024-10-08 Flagship Pioneering Innovations Vi, Llc Antigen binding molecules targeting thymic stromal lymphopoietin (TSLP)
WO2025082377A1 (zh) * 2023-10-17 2025-04-24 江苏恒瑞医药股份有限公司 一种抗tslp抗体的药物组合物及其用途

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US7982016B2 (en) 2007-09-10 2011-07-19 Amgen Inc. Antigen binding proteins capable of binding thymic stromal lymphopoietin
US8359965B2 (en) 2007-09-17 2013-01-29 Oxford J Craig Apparatus and method for broad spectrum radiation attenuation
TW201018482A (en) 2008-08-08 2010-05-16 Glaxo Wellcome Mfg Pte Ltd Novel treatment
EP2496707B1 (en) 2009-11-04 2020-02-26 Merck Sharp & Dohme Corp. Engineered anti-tslp antibody
TWI609698B (zh) * 2010-01-20 2018-01-01 Chugai Pharmaceutical Co Ltd 穩定化的含抗體溶液製劑
SMT202000095T1 (it) * 2010-05-14 2020-03-13 Amgen Inc Formulazioni di anticorpi anti-sclerostina ad alta concentrazione
WO2012007495A1 (en) 2010-07-15 2012-01-19 F. Hoffmann-La Roche Ag Antibodies specifically binding to human tslpr and methods of use
AT510032B1 (de) 2010-11-30 2012-01-15 Steiner Erwin Ing Montageeinrichtung für fassadenelemente
US9100245B1 (en) 2012-02-08 2015-08-04 Amazon Technologies, Inc. Identifying protected media files
US20140227250A1 (en) * 2012-08-23 2014-08-14 Merck Sharp & Dohme Corp. Stable formulations of antibodies to tslp
US9306926B2 (en) 2013-03-15 2016-04-05 Brian A. Truong User authentication using unique hidden identifiers
EP3209332B1 (en) * 2014-10-23 2021-05-26 Amgen Inc. Reducing viscosity of pharmaceutical formulations
AU2016231122A1 (en) 2015-03-11 2017-09-07 Glaxosmithkline Intellectual Property Development Limited TSLP binding proteins
WO2017042701A1 (en) 2015-09-09 2017-03-16 Novartis Ag Thymic stromal lymphopoietin (tslp)-binding antibodies and methods of using the antibodies
JP6897570B2 (ja) * 2015-12-18 2021-06-30 アステラス製薬株式会社 抗ヒトｔｓｌｐ受容体抗体含有医薬組成物
JOP20190243A1 (ar) * 2017-04-12 2019-10-13 Medimmune Llc علاج الربو بجسم مضاد لـ tslp
MA48461A (fr) * 2017-04-28 2020-03-04 Amgen Inc Excipients pour réduire la viscosité de formulations d'anticorps et compositions de formulation
EP3634546A1 (en) 2017-06-08 2020-04-15 Amgen Inc. Torque driven drug delivery device
CN109952093B (zh) * 2017-07-27 2022-02-08 江苏恒瑞医药股份有限公司 一种sost抗体药物组合物及其用途
EP3706826A1 (en) 2017-11-10 2020-09-16 Amgen Inc. Plungers for drug delivery devices
EP4321870A3 (en) 2018-03-13 2024-04-03 Amgen Inc. Methods for the preparation of trypsin-resistant polypeptides for mass spectrometric analysis
EP3866890A1 (en) 2018-10-15 2021-08-25 Amgen Inc. Drug delivery device having damping mechanism
AU2019359801B2 (en) 2018-10-15 2025-01-02 Amgen Inc. Platform assembly process for drug delivery device
BR112022010905A2 (pt) * 2019-12-05 2022-09-06 Sanofi Aventis Us Llc Formulações de anticorpos anti-cd38 para administração subcutânea

Also Published As

Publication number Publication date
KR20220140772A (ko) 2022-10-18
CL2022002193A1 (es) 2023-03-24
CA3166964A1 (en) 2021-08-19
UY39083A (es) 2021-08-31
BR112022016010A2 (pt) 2022-12-20
WO2021163504A1 (en) 2021-08-19
CN115279404A (zh) 2022-11-01
CO2022012868A2 (es) 2022-12-09
PE20230112A1 (es) 2023-01-27
EP4103235A1 (en) 2022-12-21
MX2022010012A (es) 2022-09-07
US20230078678A1 (en) 2023-03-16
IL295042A (en) 2022-09-01
PH12022552050A1 (en) 2024-02-12
JP2023513312A (ja) 2023-03-30
JOP20220183A1 (ar) 2023-01-30
AU2021219839A1 (en) 2022-08-25

Similar Documents

Publication Publication Date Title
PH12022552050A1 (en) Formulations of human anti-tslp antibodies and methods of treating inflammatory disease
JP7473603B2 (ja) 液体医薬組成物
JP6848046B2 (ja) Ｐｄ−１抗体製剤
HRP20241131T1 (hr) Visokokoncentrirane formulacije inhibitornih antitijela masp-2 niske viskoznosti, pribori i metode
RU2007119724A (ru) Композиции, содержащие эктинэсайдин и дисахарид
EP3156071A1 (en) Stable aqueous adalimumab preparation
RU2005128280A (ru) Композиции иммуноглобулина и способ их получения
JP2020511443A (ja) 液体医薬組成物
JP2020523402A (ja) グルタチオンジスルフィド及びグルタチオンジスルフィドｓ−オキシドを含む医薬組成物
WO2017131130A1 (ja) コンドロイチン硫酸及びヒアルロン酸を含有する安定化された水性組成物
AR117707A1 (es) Formulación de solución de proteínas que contiene una alta concentración de un anticuerpo anti-vegf
JP2008516967A (ja) 乳酸ナトリウム希釈液中にピペラシリン、タゾバクタムおよびアミノカルボン酸を含む組成物
WO2008001849A1 (fr) Agent destiné à être utilisé pour une injection comprenant un antibiotique et solution pour injection comprenant l'agent
JP6885875B2 (ja) 液体医薬組成物
EP3178927B1 (en) Protein-stabilizing agent and protein-stabilizing method
JPH11302197A (ja) ヒアルロン酸安定化組成物
AU2002334203C1 (en) Kahalalide compounds for use in cancer therapy
JP2020534366A (ja) アダリムマブ用医薬製剤
DE50310932D1 (de) Sporopollenin enthaltende lösliche zusammensetzung und verwendung
AR121329A1 (es) Formulaciones de anticuerpos anti-tslp humanos y métodos de tratamiento de una enfermedad inflamatoria
WO1997024374A1 (fr) Solution stable contenant du hyaluronate de sodium
JPH0678241B2 (ja) ｔＰＡ医薬組成物
JP6965474B1 (ja) テリパラチド又はその塩を含有するプレフィルドシリンジまたはカートリッジ製剤の振盪による白濁を抑制する方法
JPH08104642A (ja) ヒアルロン酸ナトリウム注射液用安定化組成物
RU2741948C1 (ru) Способ профилактики гиперкоагуляции у животных при стрессе